A stronger than expected gain in January producer prices lifted the markets to a higher close with the Dow climbing 92 points to 20,504. Nasdaq gained 18 points to 5,782.
On the upside
Galectin Therapeutics (Nasdaq: GALT) presented at the BIO CEO & Investor Conference.
LightPath Technologies (Nasdaq: LPTH) swung to a profit for the second quarter.
Cellect Biotechnology (Nasdaq: APOP) will voluntarily delist from the Tel-Aviv Stock Exchange.
On the downside
Aviragen Therapeutics (Nasdaq: AVIR) reported disappointing results from a Phase 2b SPIRITUS trial of vapendavir.
New Age Beverages (Nasdaq: NBEV) priced its public offering of approximately 4.29 million shares of common stock at the discounted price of $3.50 per share.
Tile Shop Holdings (Nasdaq: TTS) reported sharply lower fourth quarter earnings that fell short of analyst expectations.
In the broad market, advancing issues outpaced decliners by a margin of nearly 10 to 9 on the NYSE and by more than 10 to 9 on Nasdaq. The broader S&P 500 index gained 9 points to 2,337. Bitcoin gained $12 to $1,003.
